Iyer 2015.

Methods	Location of trial: Singapore Number of centres: not stated Funding: not stated Trial ID: not stated
Participants	Inclusion criteria: people newly diagnosed with histologically confirmed, resectable, non‐metastatic stage III/IV HNSCC who had a good Eastern Cooperative Oncology Group performance status (0 or 1) and adequate bone marrow, hepatic and renal function. Exclusion criteria: nasopharynx and salivary glands Recruitment period: August 1996 to February 2002 Number randomised: 119 Number analysed: 118
Interventions	Surgery and adjuvant RT vs concurrent CRT Group 1 (n = 60): radical surgery + adjuvant RT Group 2 (n = 59): combination chemotherapy with cisplatin and 5‐fluorouracil and concurrent RT Randomisation was stratified according to primary tumour site (oral cavity/oropharynx, larynx/hypopharynx, others) and lymph node status (lymph‐node positive vs lymph‐node negative).
Outcomes	To determine whether concurrent chemotherapy was superior to the prevailing conventional treatment at that time, namely surgery and adjuvant RT, with survival as the endpoint. Primary: overall survival, DSS, locoregional recurrence‐free survival, distant recurrence‐free survival Secondary: none noted Duration of follow‐up for all participants: 10 years
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of sequence generation not described.
Allocation concealment (selection bias)	Unclear risk	Not mentioned
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Survival was primary outcome and considered an objective outcome.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Only 1 participant missing from analysis as histopathological assessment confirmed adenocarcinoma, therefore excluded.
Selective reporting (reporting bias)	Low risk	No evidence of selective outcome reporting.
Other bias	Low risk	No other apparent bias.